News

Vutrisiran appears to effectively conserve functional capacity and quality of life (QOL) in patients with ATTR-CM.

A new study reports that treatment with acoramidis decreases the rate of all-cause mortality and cardiovascular hospitalization in patients with ATTR-CM.

A recent review article explores a variety of therapies being developed to target the root cause of ATTR-CM.

Addressing disparities in the diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) and access to care is critical to improving patient outcomes and reducing health inequities, according to a review published recently in Current Cardiology Reports. While ATTR-CM was once considered rare, growing evidence suggests that it is significantly underdiagnosed. Delayed detection and limited awareness among healthcare […]

The FDA has approved vutrisiran (AMVUTTRA®) for the treatment of ATTR-CM based on favorable results from the HELIOS-B clinical trial.

In a recent webinar, Meghan Beier, PhD, MA highlights several strategies for managing the emotional impacts of ATTR-CM.

Understanding how bacteria interact with heart and digestive health could lead to more personalized treatments for patients with ATTR.

A recent study found that needing a higher dose of diuretic can serve as a useful marker for tracking disease progression.

A case report describes a 71-year old woman who was diagnosed with hereditary ATTR-CM after experiencing post-lung transplant complications.

A patient with transthyretin amyloid cardiomyopathy (ATTR-CM) benefited from early diagnosis and treatment with an oral transthyretin stabilizer, according to a case report published recently in Cureus. The 67-year-old man experienced lessening symptoms of heart failure after starting on the stabilizer. Despite worsening shortness of breath, swelling in his legs and reduced exercise tolerance, he […]